Nuveen LLC Makes New $2.01 Million Investment in Nurix Therapeutics, Inc. $NRIX

Key Points

• Nuveen LLC has invested approximately $2.01 million in Nurix Therapeutics by acquiring 169,145 shares during the first quarter, representing around 0.22% of the company.
• Insider trading activity includes CFO Houte Hans Van selling 5,402 shares, which reflects a 13.20% decrease in their ownership, while other insiders also decreased their holdings.
• Analysts have varied opinions on Nurix Therapeutics, with price targets ranging from $26 to $34 and a consensus rating of "Moderate Buy."

Nuveen LLC acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 169,145 shares of the company's stock, valued at approximately $2,009,000. Nuveen LLC owned about 0.22% of Nurix Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Nurix Therapeutics during the fourth quarter worth approximately $28,000. Aquatic Capital Management LLC acquired a new position in Nurix Therapeutics during the 4th quarter worth $87,000. Exchange Traded Concepts LLC boosted its position in Nurix Therapeutics by 38.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after buying an additional 2,562 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Nurix Therapeutics in the 4th quarter valued at $164,000. Finally, GAMMA Investing LLC increased its stake in shares of Nurix Therapeutics by 202.2% in the 1st quarter. GAMMA Investing LLC now owns 14,018 shares of the company's stock valued at $167,000 after buying an additional 9,380 shares during the period.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NRIX. Wall Street Zen raised Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Morgan Stanley set a $16.00 target price on shares of Nurix Therapeutics and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. UBS Group reduced their target price on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, July 10th. Oppenheimer reissued an "outperform" rating and set a $30.00 price target (down from $32.00) on shares of Nurix Therapeutics in a research note on Thursday, July 31st. Finally, Stephens restated an "overweight" rating and issued a $30.00 price objective on shares of Nurix Therapeutics in a report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $28.87.

Nurix Therapeutics Stock Down 3.6%

Shares of NRIX traded down $0.34 during trading hours on Thursday, reaching $9.12. The stock had a trading volume of 474,785 shares, compared to its average volume of 698,623. The company has a market cap of $697.22 million, a P/E ratio of -3.49 and a beta of 2.10. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The firm has a 50-day moving average of $10.99 and a 200 day moving average of $11.58.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%.The firm had revenue of $44.06 million during the quarter, compared to analysts' expectations of $16.26 million. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,402 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $11.03, for a total value of $59,584.06. Following the sale, the chief financial officer owned 35,512 shares in the company, valued at approximately $391,697.36. The trade was a 13.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gwenn Hansen sold 4,308 shares of Nurix Therapeutics stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the sale, the insider owned 69,023 shares in the company, valued at $828,966.23. The trade was a 5.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,014 shares of company stock valued at $163,014 in the last three months. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.